Should we embrace or ablate our urge to (ovarian) suppress?

Journal of Clinical Oncology

Volumn 32, Issue 35, 2014, Pages 3920-3922

  Jankowitz, Rachel C ^a   Puhalla, Shannon ^a   Davidson, Nancy E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HORMONE INHIBITION; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVARIAN FUNCTION SUPPRESSION; OVARY FUNCTION; OVERALL SURVIVAL; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; OVARY; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; OVARY; TAMOXIFEN;

EID: 84918587656     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.9953     Document Type: Editorial

References (12)

1. Griggs JJ, Somerfield MR, Anderson H, et al: American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol 29:3939-3942, 2011
2. Burstein HJ, Temin S, Anderson H, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255-2269, 2014
3. Tevaarwerk AJ, Wang M, Zhao F, et al: Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative hormone receptor-positive breast cancer (E-3193, INT-0142): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32:3948-3958, 2014
4. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
5. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
6. Gray RG: aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at years in 6,953 women with early breast cancer. J Clin Oncol 31:6s, 2013 (suppl; abstr 5)
7. Pagani O, Regan MM, Walley BA, et al: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107-118, 2014
8. Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101-1108, 2011
9. Gnant M, Mlineritsch B, Stoeger H, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641, 2011
10. Pfeiler G, Königsberg R, Fesl C, et al: Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol 29:2653-2659, 2011
11. Goss PE, Ingle JN, Martino S, et al: Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 24:355-361, 2013
12. Bernhard J, Luo W, Ribi K, et al: Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 32:19s, 2014 (suppl; abstr 557)